|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date21 Dec 2020 |
|
MechanismNS3/NS4A inhibitors |
|
|
Active Indication- |
|
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
评价伏拉瑞韦、磷酸依米他韦与利巴韦林联合给药在慢性丙型肝炎基因1型受试者中的疗效和安全性III期研究
[Translation] Phase III study to evaluate the efficacy and safety of volapivir, imipenem phosphate, and ribavirin in subjects with chronic hepatitis C genotype 1
评价伏拉瑞韦胶囊、磷酸依米他韦胶囊与利巴韦林联合给药12周在慢性丙型肝炎病毒基因1型受试者中的疗效与安全性。
[Translation] To evaluate the efficacy and safety of volapivir capsules, imipenem phosphate capsules and ribavirin combined for 12 weeks in subjects with chronic hepatitis C virus genotype 1.
评价伏拉瑞韦、磷酸依米他韦与利巴韦林联合给药在慢性丙型肝炎基因1型受试者中的疗效和安全性III期研究
[Translation] Phase III study to evaluate the efficacy and safety of volapivir, imipenem phosphate, and ribavirin in subjects with chronic hepatitis C genotype 1
评价伏拉瑞韦胶囊、磷酸依米他韦胶囊与利巴韦林联合给药12周在慢性丙型肝炎病毒基因1型受试者中的疗效与安全性。
[Translation] To evaluate the efficacy and safety of volapivir capsules, imipenem phosphate capsules and ribavirin combined for 12 weeks in subjects with chronic hepatitis C virus genotype 1.
A Phase III, Multicenter, Open-labeded Study To Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and Ribavirin for 12 Weeks of Treatment in HCV Genotype I Infected Patients
A Phase III, Multicenter, open-labeded study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and Ribavirin for 12 weeks of treatment in HCV Genotype I Infected Patients
100 Clinical Results associated with Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
0 Patents (Medical) associated with Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
100 Deals associated with Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
100 Translational Medicine associated with Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.